GT Biopharma, Inc. also files under OXIS, OXIS.OB; those filings are included.
The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
| Date | Insider | Role | Action | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 4, 2025 | Breen Michael Martin | CEO and Director, Director | Grant(A) | 100K | — | $0 |
| Sep 4, 2025 | Breen Michael Martin | CEO and Director, Director | Grant(A) | 100K | — | $0 |
| Sep 4, 2025 | Casamento Charles J | Director | Grant(A) | 63K | — | $0 |
| Sep 4, 2025 | Kramer Hilary | Director | Grant(A) | 31K | — | $0 |
| Sep 4, 2025 | Breen Michael Martin | CEO and Director, Director | Grant(A) | 100K | — | $0 |
| Sep 4, 2025 | Mun-Gavin David C. | Director | Grant(A) | 31K | — | $0 |
| Sep 4, 2025 | Urban Alan Louis | Chief Financial Officer | Grant(A) | 50K | — | $0 |
| Sep 4, 2025 | Urban Alan Louis | Chief Financial Officer | Grant(A) | 50K | — | $0 |
| Oct 17, 2024 | Urban Alan Louis | Chief Financial Officer | Grant(A) | 23K | — | $0 |
| Aug 11, 2023 | Ohri Manu | CFO & Secretary | Other(J) | 200K | $0.29 | $58K |
| Aug 11, 2023 | Ohri Manu | CFO & Secretary | Other(J) | 200K | $0.29 | $58K |
| Aug 11, 2023 | Ohri Manu | CFO & Secretary | Grant(A) | 200K | $0.29 | $58K |
| Aug 11, 2023 | Breen Michael Martin | Executive Chairman/Interim CEO, Director | Grant(A) | 200K | $0.29 | $58K |
| Jun 16, 2023 | Casamento Charles J | Director | Grant(A) | 500K | — | $0 |
| Apr 11, 2023 | Breen Michael Martin | Executive Chairman/Interim CEO, Director | Buy(P) | 50K | $0.50 | $25K |
| Apr 6, 2023 | Ohri Manu | CFO & Secretary | Buy(P) | 50K | $0.50 | $25K |
| Jan 27, 2023 | Breen Michael Martin | Exec Chairman and Interim CEO, Director | Grant(A) | 500K | — | $0 |
| Jan 27, 2023 | Wendel Bruce | Director | Grant(A) | 500K | — | $0 |
| Jan 27, 2023 | Shrotriya Rajesh C MD | Director | Grant(A) | 500K | — | $0 |
| Jan 27, 2023 | Ohri Manu | Chief Financial Officer | Grant(A) | 500K | — | $0 |
| Jul 15, 2022 | Ohri Manu | CFO & Secretary | Other(J) | 100K | — | $0 |
| Jul 15, 2022 | Wendel Bruce | Director | Grant(A) | 50K | — | $0 |
| Jul 15, 2022 | Wendel Bruce | Director | Grant(A) | 50K | — | $0 |
| Jul 15, 2022 | Ohri Manu | CFO & Secretary | Grant(A) | 100K | — | $0 |
| Jul 15, 2022 | Ohri Manu | CFO & Secretary | Other(J) | 100K | — | $0 |
| Jul 15, 2022 | Ohri Manu | CFO & Secretary | Grant(A) | 200K | — | $0 |
| Jul 15, 2022 | Berk Gregory | Pres. of R&D, CMO | Grant(A) | 50K | — | $0 |
| Jul 15, 2022 | Urban Alan Louis | Director | Grant(A) | 50K | — | $0 |
| Jul 15, 2022 | Shrotriya Rajesh C MD | Director | Grant(A) | 50K | — | $0 |
| Jul 15, 2022 | Shrotriya Rajesh C MD | Director | Grant(A) | 361K | — | $0 |
| Jul 15, 2022 | Shrotriya Rajesh C MD | Director | Grant(A) | 50K | — | $0 |
| Jul 15, 2022 | Breen Michael Martin | Exec. Chair. and Interim CEO, Director | Grant(A) | 278K | — | $0 |
| Jul 15, 2022 | Breen Michael Martin | Exec. Chair. and Interim CEO, Director | Grant(A) | 50K | — | $0 |
| Dec 31, 2021 | Choy Gavin | Acting Chief Financial Officer | Grant(A) | 228K | — | $0 |
| Feb 25, 2021 | Breen Michael Martin | Director | Conversion(C) | 10K | $3.40 | $34K |
| Feb 25, 2021 | Breen Michael Martin | Director | Conversion(C) | 40K | $3.40 | $137K |
| Feb 25, 2021 | Breen Michael Martin | Director | Conversion(C) | 30K | — | $0 |
| Feb 25, 2021 | Breen Michael Martin | Director | Conversion(C) | 100K | — | $0 |
| Feb 16, 2021 | Wendel Bruce | Director | Grant(A) | 50K | — | $0 |
| Feb 16, 2021 | Shrotriya Rajesh C MD | Director | Grant(A) | 50K | — | $0 |
| Feb 16, 2021 | Breen Michael Martin | Director | Grant(A) | 278K | — | $0 |
| Feb 16, 2021 | Breen Michael Martin | Director | Grant(A) | 50K | — | $0 |
| Feb 16, 2021 | Berk Gregory | Director | Grant(A) | 278K | — | $0 |
| Feb 16, 2021 | Berk Gregory | Director | Grant(A) | 50K | — | $0 |
| Feb 16, 2021 | Wendel Bruce | Director | Grant(A) | 348K | — | $0 |
| Dec 22, 2020 | Wendel Bruce | Director | Buy(P) | 441 | $8.73as filed | — |
| Dec 22, 2020 | Weldon Steven W | Insider | Sell(S) | 48K | $0.40 | $19K |
| Dec 22, 2020 | Wendel Bruce | Director | Buy(P) | 1K | $8.87as filed | — |
| Dec 21, 2020 | Weldon Steven W | Insider | Sell(S) | 50K | $0.30 | $15K |
| Dec 21, 2020 | Weldon Steven W | Insider | Sell(S) | 36K | $0.34 | $12K |
| Dec 21, 2020 | Weldon Steven W | Insider | Sell(S) | 50K | $0.33 | $17K |
| Dec 18, 2020 | Weldon Steven W | Insider | Sell(S) | 50K | $0.30 | $15K |
| Dec 17, 2020 | Weldon Steven W | Insider | Sell(S) | 50K | $0.31 | $16K |
| Dec 17, 2020 | Weldon Steven W | Insider | Sell(S) | 50K | $0.30 | $15K |
| Dec 16, 2020 | Weldon Steven W | Insider | Sell(S) | 50K | $0.30 | $15K |
| Dec 15, 2020 | Weldon Steven W | Insider | Sell(S) | 50K | $0.30 | $15K |
| Dec 15, 2020 | Weldon Steven W | Insider | Sell(S) | 50K | $0.30 | $15K |
| Dec 15, 2020 | Weldon Steven W | Insider | Sell(S) | 50K | $0.32 | $16K |
| Dec 14, 2020 | Weldon Steven W | Insider | Sell(S) | 46K | $0.29 | $13K |
| Dec 14, 2020 | Weldon Steven W | Insider | Sell(S) | 50K | $0.29 | $15K |
| Dec 14, 2020 | Weldon Steven W | Insider | Sell(S) | 50K | $0.28 | $14K |
| Dec 11, 2020 | Weldon Steven W | Insider | Sell(S) | 50K | $0.25 | $13K |
| Dec 11, 2020 | Weldon Steven W | Insider | Sell(S) | 50K | $0.26 | $13K |
| Nov 16, 2020 | Wendel Bruce | Director | Buy(P) | 3K | $3.14as filed | — |
| Jun 2, 2020 | Cataldo Tony | CEO, Director, 10% Owner | Sell(S) | 4.2M | — | $0 |
| May 13, 2020 | Weldon Steven W | CFO, Director | Sell(S) | 2.3M | — | $0 |
| Aug 14, 2019 | Cataldo Tony | CEO, Director, 10% Owner | Grant(A) | 7.0M | — | $0 |
| Aug 14, 2019 | Weldon Steven W | CFO, Director, 10% Owner | Grant(A) | 4.5M | — | $0 |
| Feb 6, 2019 | Cataldo Tony | Director | Sell(S) | 800K | — | $0 |
| Feb 1, 2019 | Urbanski Raymond W. | CEO, Director | Sell(S) | 177K | — | $0 |
| Nov 2, 2017 | Cataldo Tony | Executive Chairman, Director, 10% Owner | Gift(G) | 200K | — | $0 |
| Nov 2, 2017 | Cataldo Tony | Executive Chairman, Director, 10% Owner | Gift(G) | 100K | — | $0 |
| Nov 2, 2017 | Cataldo Tony | Executive Chairman, Director, 10% Owner | Gift(G) | 3.0M | — | $0 |
| Sep 1, 2017 | Weldon Steven W | CFO, Director | Grant(A) | 2.6M | — | $0 |
| Sep 1, 2017 | Cataldo Tony | Executive Chairman, Director, 10% Owner | Grant(A) | 5.1M | — | $0 |
| Apr 5, 2016 | Bristol Investment Fund Ltd | 10% Owner | Other(J) | 250K | — | — |
| Apr 4, 2016 | Bristol Investment Fund Ltd | 10% Owner | Sell(S) | 675K | $303,750.00 | $205.0B |
| Mar 1, 2012 | Saloff David | CEO, Chairman of the Board, Director | Grant(A) | 26.3M | $0.04 | $1.1M |
| Aug 31, 2011 | Saloff David | Chief Executive Officer, Director | Grant(A) | 539K | $0.05 | $27K |
| May 20, 2011 | Dube Anshuman | Director | Buy(P) | 0 | $25,000.00 | $0 |
| Dec 27, 2010 | Theorem Group, LLC | 10% Owner | Sell(S) | 360K | $0.13 | $47K |
| Dec 27, 2010 | Dube Anshuman | Director, 10% Owner | Sell(S) | 360K | $0.13 | $47K |
| Dec 23, 2010 | Theorem Group, LLC | 10% Owner | Sell(S) | 340K | $0.13 | $44K |
| Dec 23, 2010 | Theorem Group, LLC | 10% Owner | Conversion(C) | 700K | $0.05 | $35K |
| Dec 23, 2010 | Dube Anshuman | Director, 10% Owner | Conversion(C) | 700K | $0.05 | $35K |
| Dec 23, 2010 | Dube Anshuman | Director, 10% Owner | Conversion(C) | 700K | $0.05 | $35K |
| Dec 23, 2010 | Dube Anshuman | Director, 10% Owner | Sell(S) | 340K | $0.13 | $44K |
| Dec 23, 2010 | Theorem Group, LLC | 10% Owner | Conversion(C) | 700K | $0.05 | $35K |
| Aug 31, 2010 | Post Gary M | Insider | Sell(S) | 70K | $0.11 | $8K |
| Aug 30, 2010 | Post Gary M | Insider | Sell(S) | 31K | $0.11 | $3K |
| Aug 26, 2010 | Post Gary M | Insider | Sell(S) | 76K | $0.12 | $9K |
| Jul 8, 2010 | Post Gary M | Secretary, Director | Sell(S) | 50K | $0.11 | $6K |
| Jul 7, 2010 | Post Gary M | Secretary, Director | Sell(S) | 35K | $0.10 | $4K |
| Jul 7, 2010 | Post Gary M | Secretary, Director | Sell(S) | 125K | $0.10 | $13K |
| Jul 7, 2010 | Post Gary M | Secretary, Director | Sell(S) | 55K | $0.11 | $6K |
| Jul 7, 2010 | Post Gary M | Secretary, Director | Sell(S) | 33K | $0.11 | $4K |
| Jul 7, 2010 | Post Gary M | Secretary, Director | Sell(S) | 100K | $0.11 | $11K |
| Jul 7, 2010 | Post Gary M | Secretary, Director | Sell(S) | 25K | $0.11 | $3K |
| Mar 29, 2010 | Post Gary M | Director | Grant(A) | 1.1M | — | $0 |
| Jan 26, 2010 | Post Gary M | Director | Option exercise(X) | 100K | — | $0 |
Insider transactions sourced from SEC EDGAR Form 4 filings, normalized within minutes of acceptance. "Buy"/"Sell" mark open-market transactions (codes P/S), the tradeable signal. Awards, option exercises and tax-withholding are shown with their raw code. All data is public domain.
Issuer: GT Biopharma, Inc., SEC CIK 0000109657. The symbol on a Form 4 is typed by the filer, so this page follows the issuer with the newest filing under GTBP and shows every filing by that issuer (also filed as OXIS, OXIS.OB).
Coverage: Form 4 filings indexed 2006-01-02 → 2026-09-12. Earlier history is backfilling; this window widens as it deepens.
Programmatic access via the Arkolith API & MCP server (insider.transactions, insider.company).
Connected pages for GTBP